Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 19/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20604296 | 0.87 | NOTUM (1.00) | NOTUMALDH1A1NR1H4 | |
| SCHEMBL10370979 | 0.87 | NOTUM (0.77) | NOTUMALDH1A1NR1H4 | |
| SCHEMBL1980763 | 0.84 | NOTUM (1.00) | NOTUMALDH1A1NR1H4 | |
| SCHEMBL1979515 | 0.84 | NOTUM (1.00) | NOTUMALDH1A1NR1H4 | |
| SCHEMBL14226118 | 0.83 | ALDH1A1 (0.71) | NOTUMALDH1A1 | |
| SCHEMBL17172477 | 0.82 | NOTUM (0.79) | NOTUMALDH1A1 | |
| SCHEMBL14226116 | 0.82 | ALDH1A1 (0.70) | NOTUMALDH1A1 | |
| SCHEMBL1981311 | 0.82 | NOTUM (0.74) | NOTUMALDH1A1NR1H4 | |
| SCHEMBL2449412 | 0.81 | PLK1 (0.73) | NOTUMALDH1A1 | |
| SCHEMBL3491793 | 0.81 | NOTUM (0.68) | NOTUMALDH1A1NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642344-B2 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES, INC. (US) | 2010-01-05 | — | — | US | claimed |
| EP-0992511-B1 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES INC (US) | 2009-03-11 | — | — | EP | claimed |
| US-20080009613-A1 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES, INC. (US) | 2008-01-10 | — | — | US | claimed |
| US-7247434-B2 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES, INC. (US) | 2007-07-24 | — | — | US | claimed |
| EP-0868535-B9 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | QIAGEN GENOMICS INC (US) | 2007-05-09 | — | — | EP | claimed |
| EP-0868535-B2 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | QIAGEN GENOMICS INC (US) | 2006-01-04 | — | — | EP | claimed |
| US-20040115694-A1 | Methods and compositions for determining the sequence of nucleic acid molecules | QIAGEN GENOMICS, INC. | 2004-06-17 | — | — | US | claimed |
| EP-0990047-B1 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY | QIAGEN GENOMICS INC (US) | 2003-05-14 | — | — | EP | claimed |
| US-20030077595-A1 | Methods and compositions for enhancing sensitivity in the analysis of biological-based assays | QIAGEN GENOMICS, INC. | 2003-04-24 | — | — | US | claimed |
| US-20020119456-A1 | Methods and compositions for determining the sequence of nucleic acid molecules | AGILENT TECHNOLOGIES, INC. | 2002-08-29 | — | — | US | claimed |
| US-6312893-B1 | GENERATING TAGGED NUCLEIC ACID FRAGMENTS WHICH ARE COMPLEMENTARY TO SELECTED TARGET NUCLEIC ACID MOLECULE; SEPARATION OF TAGGED FRAGMENTS; CLEAVING THE TAGS; DETECTING TAGS BY NON-FLUORESCENT SPECTROMETRY OR POTENTIOMETRY | QIAGEN GENOMICS, INC. | 2001-11-06 | — | — | US | claimed |
| EP-0868535-B1 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | RAPIGENE INC (US) | 2000-04-12 | — | — | EP | claimed |
| US-6027890-A | DETECTING LIGAND BINDING BY INCUBATING TAGGED MEMBERS WITH BIOLOGICAL SAMPLE, SEPARATING BOUND FROM UNBOUND MEMBERS, CLEAVING TAG, THEN DETECTING BY NON-FLUORESCENT SPECTROSCOPY OR POTENTIOMETRY | RAPIGENE, INC. (US) | 2000-02-22 | — | — | US | claimed |
| EP-0962464-A2 | Methods and compositions for detecting binding of ligand pair using non-fluorescent label | Rapigene, Inc. (US) | 1999-12-08 | — | — | EP | claimed |
| CN-112165936-B | beta-lactamase inhibitor | 国立大学法人东海国立大学机构 | 2023-11-28 | — | — | CN | disclosed |
| US-11497731-B2 | β-lactamase inhibitor | NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (JP) | 2022-11-15 | — | — | US | disclosed |
| US-20210236463-A1 | beta-LACTAMASE INHIBITOR | NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (JP) | 2021-08-05 | — | — | US | disclosed |
| EP-0962537-A2 | Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques | Rapigene, Inc. (US) | 1999-12-08 | — | — | EP | disclosed |
| EP-0962464-A2 | Methods and compositions for detecting binding of ligand pair using non-fluorescent label | Rapigene, Inc. (US) | 1999-12-08 | — | — | EP | disclosed |
| EP-0850320-B1 | METHODS FOR DETECTING BINDING OF LIGAND PAIR WITH ENHANCED SENSITIVITY | RAPIGENE INC (US) | 1999-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210236463-A1 | beta-LACTAMASE INHIBITOR | MGAM, CMBL, MGAM2 | NOTUM 65/4885ALDH1A1 683/4885NR1H4 1536/4885 |
| US-11497731-B2 | β-lactamase inhibitor | MGAM, CMBL, MGAM2 | NOTUM 74/4885ALDH1A1 747/4885NR1H4 1608/4885 |
| US-20080009613-A1 | Methods and compositions for determining the sequence of nucleic acid molecules | CPSF6, RNMT, POLM | NOTUM 658/4885ALDH1A1 3332/4885NR1H4 4241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.